Nektar Therapeutics’s Collaboration agreement with Bristol-Myers Squibb

Ambrogio Visconti

Sidley advised Nektar Therapeutics (Nasdaq:NKTR) on a global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for Nektar’s CD122-biased agonist, NKTR-214. Bristol-Myers Squibb Company…

This content is for members only.
Login to Read More Join Now
Print Friendly, PDF & EmailPrintFriendly
Avatar

Author: Ambrogio Visconti

…

This content is for members only.
Login to Read More Join Now
Print Friendly, PDF & EmailPrintFriendly